EG-011 is the first-in-class and potent Wiskott-Aldrich syndrome protein (WASP) activator. EG-011 activates the auto-inhibited form of WASP with strong actin polymerization. EG-011 has selective anti-tumor activity in lymphomas.
体外研究(In Vitro)
EG-011 (500 nM, 2 μM; 72 小时) 在淋巴瘤细胞系 (OCI-LY-19 和 REC1) 中引起剂量依赖性细胞死亡增加 (20-55%)。EG-011 (1, 10 mM; for 24, 48 小时) 对正常的 PBMC 没有细胞毒性。 EG-011 (500 nM, 5 μM; 24 小时) 导致 EG-011 敏感 (VL51) 而不是耐药 (Z138) 细胞系在 4、8 和 24 小时两种浓度下的肌动蛋白聚合增加。 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
EG-011 (200 mg/kg; 腹腔注射; 每周 5 天) 延迟带有 MCL REC-1 细胞的雌性 NOD-SCID 小鼠的肿瘤生长 (第 6 天、第 7 天、第 9 天) 和肿瘤重量,肿瘤比对照小 2.2 倍 (P<0.001)。 has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. E. Gaudio, et al. EG-011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVOANTI-TUMOR ACTIVITY AGAINST LYMPHOMA. Hematological OncologyVolume 37: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18-22 June, 2019.[2]. Filippo Spriano, et al. Abstract 1817: EG-011 is a first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity. Cancer Res (2022) 82 (12_Supplement): 1817.